DF/HCC Kidney Cancer SPORE

描述(由申请者提供)：此申请代表着肾癌卓越研究专业计划的续展，该计划源于达纳-法伯哈佛癌症中心(DF/HCC)和贝丝以色列女执事医学中心的肾癌计划。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员--贝丝以色列女执事医疗中心、达纳-法伯癌症研究所、马萨诸塞州总医院、布里格姆妇女医院、儿童医院医疗中心以及哈佛大学公共卫生学院。这一应用支持五个主要项目，包括：1)肾母细胞瘤中WTX失活的临床相关性；2)用于疾病早期检测和靶向治疗反应的肾癌生物标志物的验证；3)对血管内皮生长因子受体阻断的获得性耐药性：潜在机制和治疗选择；4)针对肾癌中的PI3-Kinase/Akt通路：作用机制和合理联合治疗的机会；以及5)树突状细胞/肿瘤融合用于肾癌的过继免疫治疗。这些项目由三个核心整合在一起。这些是：1)管理、评估和规划；2)生物统计学；以及3)组织采集、病理学和临床数据，本孢子申请概述了一项开发研究计划，其中包括一项选择和审查新项目的计划，以及4个最近资助的项目和3个可考虑未来支持的项目的例子。我们还包括一个职业发展计划，该计划概述了一种识别、支持和审查肾癌领域有才华的年轻研究人员的机制。DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为对肾癌患者具有临床意义的进步。

DESCRIPTION (provided by applicant): This application represents the renewal of the Specialized Program of Research Excellence in Kidney Cancer originating from the Kidney Cancer Program of the Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Kidney Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Clinical Correlations of WTX Inactivation in Wilms Tumor; 2) Validation of RCC biomarkers for early disease detection and response to targeted therapy; 3) Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options; 4), Targeting the PI3-Kinase/Akt Pathway in RCC: Mechanism of Action and Opportunities for Rational Combination Therapy; and 5) Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/tumor Fusions. These projects are integrated by three cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; and 3) Tissue Acquisition, Pathology and Clinical Data, This SPORE application outlines a Development Research Program which includes a plan for selection and review of new projects and examples of 4 recently funded and 3 projects that could be considered for future support. We also include a Career Development Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer.